Venclexta for Waldenstrom’s – pro
Venetoclax is well-tolerated and produces high levels of response of patients with previously treated Waldenström macroglobulinemia (WM), according results from a recent phase 2 clinical trial.Patients with refractory disease showed a lower major response rate (57%) compared with those who had relapsed disease (95%). Very good partial response rates were lower in patients who had previously received BTK inhibitors (7%) than in those who had not (27%), as well as in patients with a CXCR4 mutation (6%) versus those without the mutation (29%). The median time to response was 9 weeks in patients who previously received BTK inhibitors versus 6 weeks in those without previous BTK inhibitor exposure. according to Dr Castillo and colleagues, the time to response was not affected by relapsed/refractory disease or CXCR4 mutation status.
Castillo JJ, Gustine J, Meid K, et al. Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia. Presented at: the 60th ASH Annual Meeting and Exposition; December 1-4, 2018; San Diego, CA. Abstract 2888.